BeOne Medicines (BEIGF) Income from Continuing Operations (2015 - 2026)
BeOne Medicines (BEIGF) reported Income from Continuing Operations of 227357000.0 for Q1 2026, up 17802.13% year-over-year from N/an in Q1 2025, and up 241.88% quarter-over-quarter from 66502000.0 in Q4 2025.
BeOne Medicines (BEIGF) Income from Continuing Operations (2015 - 2026) Analysis & Trends
BeOne Medicines (BEIGF) has 12 years of Income from Continuing Operations data on file, last reported at 227357000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 227357000.0, up 17802.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 513020000.0 (up 230.75% YoY), and the FY2025 annual result was 286933000.0, up 144.5% from the prior year.
- Income from Continuing Operations rose to 227357000.0 in Q1 2026 per BEIGF's latest filing, from 66502000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 227357000.0 in Q1 2026 and troughed at 565726000.0 in Q2 2022.
- A 5-year average of 177412882.35 and a median of 151881000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations plunged 754.48% in 2022, then surged 17802.13% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 445335000.0 in 2022, then advanced by 17.47% to 367553000.0 in 2023, then jumped by 58.68% to 151881000.0 in 2024, then jumped by 143.79% to 66502000.0 in 2025, then surged by 241.88% to 227357000.0 in 2026.
- Business Quant data shows BEIGF's Income from Continuing Operations at 227357000.0 in Q1 2026, 66502000.0 in Q4 2025, and 124841000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -56.48 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 227.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.36 Mn |
| Dec 31, 2025 | 66.50 Mn |
| Sep 30, 2025 | 124.84 Mn |
| Jun 30, 2025 | 94.32 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | -151.88 Mn |
| Sep 30, 2024 | -121.35 Mn |
| Jun 30, 2024 | -120.41 Mn |
| Mar 31, 2024 | -251.15 Mn |
| Dec 31, 2023 | -367.55 Mn |
| Sep 30, 2023 | 215.41 Mn |
| Jun 30, 2023 | -381.14 Mn |
| Mar 31, 2023 | -348.43 Mn |
| Dec 31, 2022 | -445.34 Mn |
| Sep 30, 2022 | -557.56 Mn |
| Jun 30, 2022 | -565.73 Mn |
| Mar 31, 2022 | -435.20 Mn |
| Dec 31, 2021 | -590.68 Mn |
| Sep 30, 2021 | -438.11 Mn |
| Jun 30, 2021 | -480.34 Mn |